CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 19, 2011
Result type: Reports
Project Number: SR0251-000
Product Line: Reimbursement Review

Generic Name: Belimumab

Brand Name: Benlysta

Manufacturer: GlaxoSmithKline Inc.

Therapeutic Area: Systemic lupus erythematosus

Indications: Systemic lupus erythematosus

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 25, 2012

Recommendation Type: Do not list